SCHEMBL30869797

SCHEMBL30869797

CC(C)(C)OC(=O)N1C[C@H]2C[C@@H]1CN2CCN1c2ccc(-c3cnc4[nH]ncc4c3)cc2Sc2cc(-c3cnc4[nH]ncc4c3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.39
FGFR2 P21802 1/20 0.39
FGFR4 P22455 1/20 0.39
FGFR3 P22607 1/20 0.39
KDR P35968 1/20 0.39
NAMPT P43490 1/20 0.37
KCNK3 O14649 4/20 0.37
KCNK9 Q9NPC2 4/20 0.37
ABL1 P00519 1/20 0.37
PIK3C3 Q8NEB9 3/20 0.36
RET P07949 2/20 0.36
GPR119 Q8TDV5 1/20 0.34
CHRNA7 P36544 2/20 0.34
PIK3CD O00329 1/20 0.34
KCNH2 Q12809 1/20 0.34
HDAC1 Q13547 1/20 0.34
SPR P35270 1/20 0.34
PARP1 P09874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30869658 0.84 CHRNA7 (0.47) ABL1PIK3C3CHRNA7KCNH2
SCHEMBL30869669 0.82 ABL1 (0.36) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869490 0.80 PIK3CD (0.42) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869457 0.80 PIK3CD (0.42) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869536 0.79 HSD11B1 (0.40) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869666 0.79 PIK3CD (0.41) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869607 0.79 PIK3CD (0.41) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869591 0.79 PIK3CD (0.41) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869402 0.73 CHRNA7 (0.47) PIK3C3CHRNA7KCNH2
SCHEMBL30869774 0.72 PARP1 (0.38) FGFR1FGFR2FGFR4FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070880-A1 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES, INC. (US) 2026-03-12 US disclosed
EP-4583868-A2 DYNAMIN ACTIVATORS Walden Biosciences, Inc. (US) 2025-07-16 EP disclosed
WO-2024054661-A2 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES (US) 2024-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070880-A1 DYNAMIN ACTIVATORS DNM1, DNM1L, DNM2 FGFR1 1430/4885FGFR2 2027/4885FGFR4 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.